Core Thesis - SkyWater Technology, Inc. (SKYT) is positioned for significant growth, targeting revenue increases from approximately $342 million in 2024 to over $600 million by 2026, with a long-term goal of reaching $1.7 billion by 2035 [2] Company Overview - SkyWater operates as a pure-play technology foundry in the semiconductor sector, providing development, manufacturing, and packaging services in the U.S. [2] - The company is focusing on becoming a foundational partner for next-generation computing, particularly in superconducting integrated circuits and photonics [3] Competitive Advantage - SkyWater's "Technology as a Service" (TaaS) model differentiates it from traditional contract manufacturers, allowing for co-development of chips within its fabrication environment [3] - The company's "Trusted" status with the U.S. Department of Defense creates a strong competitive moat, particularly for government and defense-related programs [4] Financial Performance - Operating leverage is beginning to emerge, with GAAP gross margins reaching 24% in Q3 2025, and margins are expected to expand as the business transitions from R&D-heavy programs to higher-volume wafer services [4] - Strategic investments, such as the acquisition of Fab 25 for approximately $93 million, have significantly increased revenue capacity [5] Market Position and Future Outlook - The company is capital intensive but is well-positioned to benefit from government initiatives like the CHIPS and Science Act, which could lead to a significant valuation rerating [5] - SkyWater's stock price has appreciated by approximately 148.6% since previous bullish coverage, indicating strong market confidence in its long-term revenue scaling and operating leverage [7]

Core Thesis - SkyWater Technology, Inc. (SKYT) is positioned for significant growth, targeting revenue increases from approximately $342 million in 2024 to over $600 million by 2026, with a long-term goal of reaching $1.7 billion by 2035 [2] Company Overview - SkyWater operates as a pure-play technology foundry in the semiconductor sector, providing development, manufacturing, and packaging services in the U.S. [2] - The company is focusing on becoming a foundational partner for next-generation computing, particularly in superconducting integrated circuits and photonics [3] Competitive Advantage - SkyWater's "Technology as a Service" (TaaS) model differentiates it from traditional contract manufacturers, allowing for co-development of chips within its fabrication environment [3] - The company's "Trusted" status with the U.S. Department of Defense creates a strong competitive moat, particularly for government and defense-related programs [4] Financial Performance - Operating leverage is beginning to emerge, with GAAP gross margins reaching 24% in Q3 2025, and margins are expected to expand as the business transitions from R&D-heavy programs to higher-volume wafer services [4] - Strategic investments, such as the acquisition of Fab 25 for approximately $93 million, have significantly increased revenue capacity [5] Market Position and Future Outlook - The company is capital intensive but is well-positioned to benefit from government initiatives like the CHIPS and Science Act, which could lead to a significant valuation rerating [5] - SkyWater's stock price has appreciated by approximately 148.6% since previous bullish coverage, indicating strong market confidence in its long-term revenue scaling and operating leverage [7]

We came across a bullish thesis on Biohaven Ltd. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on BHVN. Biohaven Ltd.'s share was trading at $11.54 as of February 18th. 25 Best Work-Life Balance Jobs to Enjoy Life Photographee.eu/Shutterstock.com Biohaven Ltd. is a clinical-stage biotechnology company targeting large global markets with significant unmet needs across neurology, immunology, and oncology, with lead programs such as its Kv7 activator franchise rep ...

Core Thesis - Biohaven Ltd. is positioned as a promising investment opportunity due to its potential blockbuster programs and a robust pipeline, with shares trading at $11.54 as of February 18th [1][3]. Company Overview - Biohaven Ltd. is a clinical-stage biotechnology company focusing on neurology, immunology, and oncology, with significant unmet needs in these areas [3]. - The company's lead programs, particularly its Kv7 activator franchise, could justify a substantial increase in market capitalization from approximately $1.4 billion if one or two Phase 3 trials succeed [3]. Long-term Vision - The company aims to evolve into a multi-franchise, platform-driven biopharma utilizing proprietary technologies, which could create a sustainable innovation engine [4]. - A single late-stage success could validate the broader platform and enhance the company's competitive advantage, which is supported by proven execution and a diversified pipeline [4]. Financial Position - Biohaven remains loss-making with negative free cash flow, typical for high-growth biotech firms, indicating that returns are heavily reliant on clinical milestones [6]. - The company has implemented a 60% reduction in R&D spending to extend its financial runway, while also securing a $600 million non-dilutive agreement to strengthen its financing position [5]. Market Sentiment and Risks - Investor confidence has been pressured by fragmentation across therapeutic areas and a recent setback with a Complete Response Letter, contributing to stock volatility [5]. - The market currently discounts the potential for a five-fold valuation increase to about $7 billion due to execution risks and pipeline uncertainties, creating a high-volatility but asymmetric long-term investment opportunity [6].

We came across a bullish thesis on Fortis Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on FTS. Fortis Inc.'s share was trading at $56.33 as of February 18th. FTS’s trailing and forward P/E were 22.70 and 21.41 respectively according to Yahoo Finance. energy Energy transmission lines. Photo by Snapwire on Pexels Fortis Inc. is positioned as a regulated electric and gas utility delivering predictable, rate-base-driven growth rather than hyper-growth. The co ...

We came across a bullish thesis on Intellia Therapeutics, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on NTLA. Intellia Therapeutics, Inc.'s share was trading at $12.48 as of February 18th. Best Innovative Stocks To Buy Now Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. NTLA represents a potentially transformative opportunity in the biotechnology space, anchored by its ...

Core Thesis - Intellia Therapeutics, Inc. (NTLA) is positioned as a transformative player in the biotechnology sector, focusing on curative genome editing treatments through in-vivo CRISPR technology [2][3] Company Overview - Intellia is a clinical-stage gene editing company that has demonstrated systemic CRISPR efficacy in humans, targeting diseases such as ATTR amyloidosis and hereditary angioedema with one-time treatments [2] - The company is among the first to explore a new drug category termed "genomic surgery," supported by partnerships with major pharmaceutical companies like Regeneron, Novartis, and Vertex [3] Market Opportunity - The market potential for Intellia is substantial, with ATTR and HAE representing multi-billion-dollar markets, and one-time therapy pricing expected to range from $500,000 to $2 million per patient [4] - Gross margins for these therapies could exceed 80%, with potential expansion into oncology and CNS disorders [4] Financial Position - Intellia maintains a strong balance sheet with over $700 million in cash and a low-debt structure, providing a financial runway of 2–3 years without the need for additional financing [5] - The company has significant institutional backing, including major biotech funds and Regeneron, although stock volatility may occur in risk-off market conditions [5] Value Creation Path - Upcoming catalysts for value creation include Phase 2/3 data for NTLA-2001 (ATTR), Phase 2 data for NTLA-2002 (HAE), FDA regulatory feedback, and potential commercial filings [6] - The bull case suggests that multiple approved drugs could validate Intellia's platform, potentially driving a market capitalization of $20–30 billion [7] Comparative Analysis - Intellia's in-vivo CRISPR work and its optionality across monogenic diseases are highlighted as key differentiators compared to other companies in the sector, such as CRISPR Therapeutics AG [8]

We came across a bullish thesis on Omnicell, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on OMCL. Omnicell, Inc.'s share was trading at $38.61 as of February 18th. OMCL’s trailing P/E was 912.50 according to Yahoo Finance. Why Impact Biomedical Inc. (IBO) Surged On Thursday? Elena Pavlovich/Shutterstock.com Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies th ...

Core Thesis - Omnicell, Inc. is positioned for transformative growth by shifting from hardware-driven revenue to a software- and services-led model, with a current share price of $38.61 and a trailing P/E of 912.50 [1][2] Group 1: Revenue and Growth Strategy - The company is currently generating approximately $1.18 billion in revenue and aims to double sales to around $2.4 billion by 2031, primarily through high-margin SaaS offerings and Expert Services [3] - Strategic acquisitions, such as ANiGENT in October 2025, are expanding Omnicell's footprint in drug diversion detection, enhancing recurring revenue streams [3] Group 2: Market Position and Competitive Advantage - Long-term growth is anticipated from the vision of an "Autonomous Pharmacy," where AI and robotics manage all medication handling, addressing healthcare labor shortages expected by 2030 [4] - Omnicell's competitive advantage includes high switching costs, over 900 patents, and a large installed base that supports proprietary AI capabilities, although competition from companies like Becton Dickinson necessitates ongoing innovation [4] Group 3: Financial Outlook and Valuation - As recurring revenue approaches nearly 50% of total revenue, margins are projected to expand from the low teens to the mid-20s, supported by strategic acquisitions and debt reduction [5] - The bull case suggests a potential fivefold increase in valuation if Annual Recurring Revenue (ARR) exceeds $1.5 billion, with a market re-rating from a traditional medical equipment multiple to a Healthcare IT multiple [6]

We came across a bullish thesis on VICI Properties Inc. on Compounding Dividends’s Substack. In this article, we will summarize the bulls’ thesis on VICI. VICI Properties Inc.'s share was trading at $29.86 as of February 17th. VICI’s trailing and forward P/E were 11.14 and 10.14 respectively according to Yahoo Finance. REIT Stocks Northstar Realty Finance NRF g0d4ather / shutterstock.com VICI Properties (VICI) is a real estate investment trust that owns one of the largest portfolios of market-leading ga ...